Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – Tingo Inc. (TMNA) Announces Q1 2022 Financial Results

Posted on May 16, 2022 by MissionIR

Tingo (OTC: TMNA), the leading agri-fintech company operating in Africa, has filed its quarterly report on Form 10-Q, wherein the company reported its financial results for the three months ended March 31, 2022. Among the highlights, Tingo reported $257.1 million and $65.5 million in consolidated revenue and operating income, respectively, during the first quarter of 2022. In addition, the company announced a 19.2% quarter-on-quarter growth in gross profit to $153.2 million, up from $128.5 million for Q4 2021. “We are very pleased to report strong operating performance for the first quarter of 2022 and the continued growth of our agri-fintech business,” said Tingo CEO Dozy Mmobuosi. “With the imminent launch of our ‘SuperApp,’ and the continue d development and expansion of our agri-fintech services, we aim to generate more commercial opportunities for our existing customers, as well as incentivize more rural farmers and communities to become subscribers and utilize our marketplace and financial technology platforms. We also look forward to accelerating our expansion throughout Africa, and now into Asia.”

To view the full press release, visit https://ibn.fm/PtVMM

About Tingo Inc.

Tingo is the leading agri-fintech company operating in Africa, with a marketplace platform that empowers social upliftment through mobile, technology and financial access for rural farming communities. Tingo’s novel “device-as-a-service” model allows the company to add market leading applications to enable customers to trade, buy top ups, pay bills, access insurance and lending services. With 9.3 million existing customers, Tingo is seeking to expand its operations across select markets in Africa. Tingo’s strategic plan is to become the eminent pan-African agri-fintech business, delivering social upliftment and financial inclusion to millions of SME farmers and women-led businesses. For more information, visit the company’s website at www.TingoInc.com.

NOTE TO INVESTORS: The latest news and updates relating to TMNA are available in the company’s newsroom at https://ibn.fm/TMNA

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Tingo Inc. TMNA | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2022 Financial, Corporate Update

Posted on May 16, 2022 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released its first quarter 2022 financial report along with key updates on company strategies. The report pointed to recent approvals of a potentially pivotal Berubicin study in Europe that is expected to significantly drive patient enrollment and opportunities for Berubicin to be used in additional oncology indications with significant unmet needs and also noted that CNSP was granted fast track designation for Berubicin from the FDA, which provides more frequent interactions with the agency to expedite the development and review process; the company had already received orphan drug designation for the novel anthracycline. Financial numbers for the period ended March 31, 2022, include a net loss of an estimated $2.8 million compared to approximately $3.6 million for the comparable period in 2021; R&D expenses of $1.5 million for Q1, down from approximately $2.2 million for the same period in 2021; and general and administrative expenses totaling some $1.3 million for the first quarter, remaining fairly constant when compared to $1.4 million for Q1 2021. “Since the start of 2022, we have significantly expanded our international presence with clinical approvals in Spain, France and Switzerland received for our potentially pivotal study of Berubicin for the treatment of GBM,” said CNS Pharmaceuticals CEO John Climaco said in the press release. “Once again, our team demonstrated its operational, clinical and regulatory expertise this quarter. These efforts enable us to continue building momentum with patient enrollment — the cornerstone of any successful drug development program. The unmet need in GBM is enormous and knows no geographic borders, and this critically important and state of the art trial will, most importantly, advance a much-needed potential treatment option to patients. We have been and remain laser focused on executing on all of our operational efforts and look forward to an exciting year ahead.”

To view the full press release, visit https://ibn.fm/ygBMy

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer. Additionally, CNS Pharmaceuticals is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain, pancreatic and ovarian cancers as well as lymphomas. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN), LGG Report on Vehicle Pack Development of Battery Cell Tech

Posted on May 16, 2022 by MissionIR

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has released an update on its partnership with Linghang Guochuang Group (“LGG”). According to the update, the two companies are working together to take solid-state polymer battery cell technology into vehicle pack level development, with solid-state polymer batteries being anticipated to be available for the second generation of the Mullen FIVE EV Crossover. The two companies announced their partnership in 2019 and then progress was sidelined in 2020 because of COVID-19 outbreak. Recently, Mullen and LGG have picked up again, starting integration of the solid-state polymer cell technology into the vehicle pack level, with plans to integrate solid-state polymer batteries into the second-generation Mullen FIVE EV Crossover, giving the EV a potential range of 600 miles on a full charge with more than 300 miles of range delivered in 18 minutes when using DC fast charging. “I am pleased to announce today that Mullen Automotive and LGG are moving forward on solid-state vehicle pack level development,” said Mullen Automotive CEO and chair David Michery in the press release. “Scaling from the cell level to pack level development is a major accomplishment and one I am proud to announce is progressing with LGG as our partner.”

To view the full press release, visit https://ibn.fm/PXDVM

About Mullen Automotive Inc.

Mullen is a southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Mullen Automotive Inc. MULN | Leave a comment

MissionIRNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Strategic Appointment of Cannabis Regulatory Veteran

Posted on May 16, 2022 by MissionIR

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced its appointment of regulatory veteran Holly Bell as vice president of regulatory affairs. According to the update, Bell will play a crucial role in Flora’s domestic and global expansion strategy and lead government relations in key international markets. “Holly’s unique knowledge and understanding of the United States’ regulatory framework will position us to make thoughtful, educated and bold decisions regarding strategic distribution, cultivation and sales plans,” said Luis Merchan, president and CEO of Flora Growth. “We look forward to bringing Holly’s expertise to our growing roster of industry standouts and working closely with governments worldwide to break down the barriers to the cannabis trade.”

To view the full press release, visit https://ibn.fm/KY1hr

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the most extensive outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions. Visit www.FloraGrowth.com or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Flora Growth Corp. FLGC | Leave a comment

Knightscope, Inc.’s (NASDAQ: KSCP) Autonomous Security Robots Facilitating Situational Crime Prevention

Posted on May 16, 2022 by MissionIR
  • The various opportunity-reducing methods of situational crime prevention look to increase the perceived risks of committing a crime, enhance the effort required to commit crimes, reduce rewards, and eliminate excuses for crime
  • Knightscope’s autonomous security robots (“ASRs”), which are equipped with capabilities such as video recording and streaming capabilities, thermal anomaly detection, facial recognition, and more, help to increase the perceived risks associated with criminal activities, resulting in deterrence
  • Following the deployment of ASRs, Knightscope’s clients have reported considerable reductions in the number of crimes reported
  • Knightscope recently added another client – a New York shopping center – and visited additional towns as part of its Robots Roadshow, with recent touchdowns in Columbus and Akron, Ohio

In a 1998 paper, Marcus Felson and Ronald V. Clarke, then Professors at the Rutgers University School of Criminal Justice in New Jersey, presented the ten principles of crime opportunity theory (https://ibn.fm/uUFqw), one of which guides the operations of Knightscope (NASDAQ: KSCP), an advanced security technology company that builds fully autonomous security robots (“ASR”).

The eighth principle states that crime can be prevented by reducing opportunities. And basing their discussion of this principle on situational crime prevention, the academics noted that the opportunity-reducing methods of situational crime prevention, such as using surveillance technologies, controlling access to targeted assets, and more, “aim, (i) to increase the perceived effort of crime, (ii) to increase the perceived risks, (iii) to reduce the anticipated rewards, and (iv) to remove excuses for crime.” 

Knightscope packages capabilities such as eye-level 360-degree HD video streaming and recording, thermal anomaly detection, license plate recognition, people detection, facial recognition, two-way intercom, the ability to operate round the clock and access ramps (mobile robots), and more into the different models of its ASRs, creating reliable security robots that increase the perceived risks of crime by providing 24/7/365 eye-level mobile surveillance. 

This surveillance, Knightscope’s website notes, “provides unprecedented deterrence capabilities, increased awareness with a conspicuous physical presence, and high-quality evidence to prosecute criminals.” And through the Knightscope Security Operations Center (“KSOC”) browser-based user interface, security personnel can interact with the robots as well as receive live alerts and access real-time data, which better informs them on how to secure people, infrastructure, and assets within a given location.

Since the initial rollout of the company’s mobile outdoor K5 ASR, the mobile indoor K3 ASR, and the stationary indoor K1 ASR in 2015, 2016, and 2017, respectively, Knightscope has emerged as a leader in developing autonomous security capabilities that offer deterrence, detection, and even report incidences of crime. The results have been reductions in crime, with Knightscope’s clients documenting wins such as a 46% drop in crime reports in the City of Huntington Park, Los Angeles County, a reduction in the number of 911 calls originating from a Las Vegas Apartment Complex, and an augmented sense of security within installations and car parks, just to mention a few (https://ibn.fm/pnHiA). And more and more potential clients are taking note of these outcomes. 

Recently, Knightscope reported it had signed a new contract with the owner of a shopping center located in Yonkers, New York. Under the terms of the agreement, Knightscope will deploy its K5 ASR to protect the center’s parking lots and structures, helping deter common challenges such as catalytic converter theft, criminal mischief, and trespassing, while simultaneously guaranteeing the safety of employees (https://ibn.fm/OxJKc).

The latest contract follows on the heels of numerous other deployments reported last month. On April 28, for example, the company received a subscription-based order to deploy 2 K5 ASR and 1 K1 ASR with a San Francisco Bay Area biotech real estate development (https://ibn.fm/Yw1ax). This announcement came a few days after Knightscope separately celebrated deployments with two new clients that have each operated for a century or more; the first, a centuries-old consumer food manufacturer and Fortune 500 company (https://ibn.fm/gEni0). The second is a 100-year-old, 4th generation recycling center (https://ibn.fm/PMGiC).

Still, Knightscope is looking to further advance its market expansion by boosting the market’s awareness of its offerings through its Robot Roadshow. An engaging experiential event aimed at grabbing attention, building direct connections with potential clients, and sparking conversations, the Robot Roadshow has so far made 38 landings in 14 states and Washington D.C., with its most recent touchdowns being in Columbus, Ohio, on May 4 (https://ibn.fm/fIc1U), and Akron, Ohio on May 5 (https://ibn.fm/0gt5E).

For more information, visit the company’s website at www.Knightscope.com, and if you have a need for the subscription-based physical security service, you may request a private demonstration of the technology at www.Knightscope.com/demo. 

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content

Posted in Knightscope Inc. KSCP | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Devoting Research, Product Development to Make Drug Substances More Effective

Posted on May 13, 2022 by MissionIR

Lexaria Bioscience Corp. (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in the approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many obstacles that may hinder their proper use by patients. “One area of Lexaria’s research has focused on pursuing U.S. Food and Drug Administration (‘FDA’) approval to begin formal, registered clinical testing of its DehydraTECH-processed cannabidiol (‘CBD’) for the treatment of hypertension under the Investigational New Drug (‘IND’) process,” a recent article reads. “Lexaria recently announced the launch of its HYPER-H21-4 randomized, double-blinded, placebo-controlled, cross-over study of DehydraTECH-CBD in relation to hypertension, with the potential for enhancing Lexaria’s ability to treat cardiovascular and other disease states beyond hypertension that are related to increased arterial stiffness. Lexaria has already completed other human studies. Last year, studies HYPER-H21-1 and HYPER-H21-2 provided evidence that DehydraTECH-CBD successfully reduced blood pressure in similarly hypertensive human volunteers, and Lexaria announced earlier this month that it had completed all data analyses of its HYPER-H21-3 study with positive safety and efficacy findings.”

To view the full article, visit https://ibn.fm/2bitq

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX 

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 Fiscal 2022 Financial Results, Provides Business Update

Posted on May 13, 2022 by MissionIR

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced financial results for the third quarter ended March 31, 2022. “The third quarter of fiscal 2022 saw noticeable advancements across all of our programs, including commencing sales of the rare cannabinoids CBDV and CBT as raw ingredients for the health and wellness industry,” said Eric A. Adams, InMed president and CEO. “For the remainder of fiscal 2022, we will remain focused on driving our commercial operations by expanding our product portfolio, increasing sales of our existing and new rare cannabinoids, exploring new distribution channels and optimizing our product development and supply chain strategy. We continue to grow revenues and have established a solid platform upon which to build as we commercialize additional high value products. We continue to focus on enhancing our sales and marketing efforts to support increasing demand.”

To view the full press release, visit https://ibn.fm/B30La

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces Q2 Preliminary Financial Results

Posted on May 13, 2022 by MissionIR

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced preliminary financial results (subject to change) for its period ending March 31, 2022. Among the highlights, the company reported cash and cash equivalents amounting to $65.2 million, as well as total debt of $22.1 million continuing its downward trend. In May 2022, Mullen signed a proposal with Thurner Design for the vehicle development of the Mullen FIVE RS, a high-performance EV sport crossover vehicle featuring close to 1,100 HP, 0-60 mph in just 1.95 seconds, and 200 mph top speed. Further, Mullen FIVE reservations increased substantially and more than doubled the volume attained in the last quarter of 2021, which included the world debut of the Mullen FIVE at the Los Angeles International Auto Show in November 2021. Reservation progress continues to build, showing strong consumer interest.

“We have made significant progress during the second quarter and have demonstrated significant finance progress for moving forward,” said David Michery, CEO and chairman of Mullen Automotive. “Our balance sheet continues to improve, and our EV programs are all moving forward, including the start of the Mullen FIVE RS program.”

To view the full news release, visit https://ibn.fm/h0RSJ

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Mullen Automotive Inc. MULN | Leave a comment

Golden Matrix Group Inc. (NASDAQ: GMGI) Leading to Way to Better Player Retention, Profits

Posted on May 13, 2022 by MissionIR
  • GMGI white labels turnkey online casino, sportsbook, and live gaming content solutions complete with a single wallet for players for both desktop and mobile applications
  • Y-o-Y revenue soared 355% to $8.88 million in Q1 fiscal 2022 with 500+ different casino brands and over 6 million players supporting GMGI’s 14th straight profitable quarter
  • Golden Matrix recently acquired R Kings Competition, a leading competitions platform that generated more than $29 million in revenue and net income above $2.4 million in the recent year

With online wagering becoming increasingly popular – and legalized in 18 U.S. states so far since PAPSA was overturned in 2018 – the race is always on to capture users. Odds are that most people have seen an advertisement offering lucrative incentives trying to lure bettors to a particular platform. In the world of B2C (business-to-consumer) gaming, there is a fine balance that needs to be struck between user acquisition expense and revenue per user, an equilibrium that most digital platforms fail to maintain.

Gaming companies don’t mind giving out $100, $200, $300 to a new user under the contention that they will get much more back in the long run. Thing is, it’s not that simple and many gaming companies struggle to ever reach profitability due to customer acquisition costs outweighing revenue generation.

“It sounds like it’s a secret recipe of some sort. It’s a real basic situation, in [B2C] gaming, it depends on how much it costs you to acquire players and, in the longer term, how much you can generate from those players,” explained Brian Goodman, CEO of online gaming platform developer and licensor Golden Matrix Group (NASDAQ: GMGI), in an interview in January with Zingernation. 

Golden Matrix historically has been focused on business-to-business (“B2B”) operations, providing online gaming companies with the tools they need to improve profits and reduce churn, industry nomenclature for losing players. Golden Matrix IP includes its flagship GM-X System and its recently released next-gen GM-Ag System that is regarded as the industry benchmark delivering access to 10,000+ games from more than 25 game providers. The white label platform offers turnkey online casino, sportsbook, and live gaming content solutions complete with a single wallet for players for both desktop and mobile applications.

Most of Golden Matrix’s business comes from Asia Pacific, but management is looking to expand closer to home. In March, the company applied for a Mexican gaming license.

Today, more than 500 different casino brands and over 6 million players use the GM-X System. If there is a secret sauce, it is the wide array of games offered by Golden Matrix in combination with aggregating and managing data. GMGI technology helps gaming companies better understand their players – skill level, what they like to play and for how long, etc. – with analytics tools that are critical to reducing churn and costs while generating additional revenue.

The growing client list translates directly to Golden Matrix’s top and bottom lines. During the first quarter of fiscal 2022 (ended 1/31/2022), GMGI posted record revenue of $8.88 million, up 355% from $1.95 million a year earlier, and net profit of $349,379, up from $52,158 in Q1 2021. In a market where finding profitability is somewhat scarce, Golden Matrix boast a string of 14 consecutive profitable quarters.

The Las Vegas-based company recently made its foray into the B2C market, acquiring 80% of U.K.-based R Kings Competitions Ltd., one of Ireland’s and England’s leading independent online competition companies, with an option for the remaining 20%. During 2020 and 2021 R Kings awarded total prizes valued at more than $54 million, comprised of residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. Current competitions at R Kings today include those ranging from drones to a BMW 320D M Sport.

With the acquisition, Golden Matrix took majority ownership of a company approximately twice its size. During the fiscal year ended October 31, 2021, R Kings generated more than $29 million in revenue and net income above $2.4 million. They also acquired nearly half a million social media followers and 25,000+ active monthly clients.

As Goodman told Zingernation, the economics of R Kings B2C model are ideal for scaling. The company spends less than a pound to acquire a player and generates north of 20 pounds from each one. Metrics like that means R Kings can favorably keep buying users. The R Kings platform is being optimized by integrating GMGI technologies where appropriate.

Goodman added that his company is on the hunt for additional positive cashflow companies that could be immediately accretive and complementary to its core technologies.

For more information, visit the company’s website at www.GoldenMatrix.com. 

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content

Posted in Golden Matrix Group Inc. GMGI | Leave a comment

MissionIRNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Expands Global Footprint to Establish Presence in the UK and EU

Posted on May 12, 2022 by MissionIR

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced expansion of its operational footprint in Europe and the United Kingdom, furthering its international growth strategy. According to the update, the London-based offices will serve as the regional headquarters for Flora’s sales force and management of its distribution centers in the U.K. and Netherlands. Flora additionally bolsters its strategic positioning in the region by partnering with Hoshi to distribute the company’s broader product portfolio to 11 countries, including Germany, Portugal, the U.K., Italy, Poland, the Czech Republic, Denmark, the Netherlands, Switzerland, Malta, and Macedonia. “Establishing our roots in the U.K. and EU will not only afford us opportunities to increase our distribution and grow market share, but it will generate actionable market insights for our team to continue to innovate and deliver the most compelling experiences we can,” said Luis Merchan, president and CEO of Flora. “The latest global expansion highlights our commitment to driving exponential growth and scale.”

To view the full press release, visit https://ibn.fm/aqFb5

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the most extensive outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions. Visit www.FloraGrowth.com or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Flora Growth Corp. FLGC | Leave a comment